Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07279467 · ClinicalTrials.gov registry record
Study of Oral Food Challenge Biomarkers (SAFER)
A clinical trial, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Not yet
- Registry status
- 500
- Enrollment target
NCT07279467: Clinical Trial study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT07279467 is a clinical trial that has not yet begun recruiting, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 500 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07279467 has not yet begun recruiting, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- NOT YET RECRUITING
- Registry status
- 500 participants
- Enrollment target
Study Summary
This is a multi-center, mechanistic study. It is designed to learn more about signs in the body, called biomarkers, that might show if someone will have a reaction to peanut during a feeding test. The trial will enroll children ages 12 months to17 years old who are suspected of having an allergy to peanut. The primary objective is to identify a biomarker (or a combination of biomarkers) that will predict oral food challenge (OFC) (feeding test) results for participants with suspected peanut allergy.
Primary Outcome
The cumulative quantity of peanut protein consumed during an oral food challenge at which dose-limiting symptoms occur, categorized as: 3-143 mg (low threshold); 443-1043 mg (medium threshold); 2043-highest cumulative, age-dependent dose (high threshold); or no reaction. The maximum cumulative dose of peanut protein for completion of the oral food challenge (OFC) is 4043 mg for participants aged 1 to 3 years and 6043 mg for participants aged 4 to 17 years. Participants ≤3 years are not required
Interventions
- DRUG Oral Food Challenge (OFC): Peanut Protein
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2026-04 |
| Est. Completion | 2027-10-01 |
What is known before NCT07279467 opens enrollment
NCT07279467 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Oral Food Challenge (OFC): Peanut Protein is the first listed.
NCT07279467 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07279467 about?
NCT07279467 is a clinical study titled "Study of Oral Food Challenge Biomarkers (SAFER)". This is a multi-center, mechanistic study. It is designed to learn more about signs in the body, called biomarkers, that might show if someone will have a reaction to peanut during a feeding test. The trial will enroll children ages 12 months to17 years old who are suspected of having an allergy to ...
What is the current status of trial NCT07279467?
This trial is currently not yet recruiting. The enrollment target is 500 participants. The study started on 2026-04. Estimated completion is 2027-10-01.
What interventions are being tested in trial NCT07279467?
The interventions under investigation include: Oral Food Challenge (OFC): Peanut Protein (DRUG).
Who is sponsoring clinical trial NCT07279467?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia